Changsha Kinergy Biotechnology

Kinergy Biopharmaceutical is a clinical-stage biotechnology company based in Changsha, China, specializing in the development of small molecule inhibitors for oncology and metabolic diseases. The company's research focuses on the Integrated Stress Response (ISR) pathway, particularly targeting the GCN2 kinase to modulate the tumor microenvironment and enhance anti-tumor immunity. Its lead candidate, K-832, is a first-in-class GCN2 inhibitor currently in Phase 1 clinical trials for patients with advanced solid tumors. Kinergy leverages a proprietary kinase-targeted drug discovery platform to identify novel chemical entities with optimized pharmacological profiles. The company maintains research and development facilities in both Changsha and Shanghai to support its growing pipeline of precision medicines.